AGuIX®: an innovative nanodrug with the aim to improve radiotherapy treatment of cancer
« NH TherAguix has developed an innovative nano drug to improve cancer treatment by radiotherapy. Its pharmacological properties and its mode of action by bio-distribution allow it to act in the heart of tumors and confer it a pan-cancer potential.
This is a tremendous hope for many patients whose medical needs are currently unmet. »
Vincent Carrère, CEO of NH TherAguix
NH TherAguix announced the appointment of Vincent Carrère as Chief Executive Officer (CEO).
NH TherAguix announced the appointment of Jean-Philippe Del as Chief Financial Officer (CFO).
T1 Mapping From MPRAGE Acquisitions: Application to the Measurement of the Concentration of Nanoparticles in Tumors for Theranostic Use
J Magn Reson Imaging. 2022 Oct 31. doi: 10.1002/jmri.28509A. Lavielle, F. Boux, J. Deborne, et al.